Table 4

Secondary analyses of counts of ambulance and ED contacts, mean and SD, unadjusted (IRR) and adjusted incidence rate ratios (AIRR) and 95% CIs comparing use of emergency healthcare postrelease according to opioid agonist treatment (OAT) use in the first 3 months postrelease among a cohort of men who regularly injected drugs prior to imprisonment stratified by postrelease OAT exposure and frequency of opioid use

OutcomeCount of contactsMean of contacts (SD)IRR (95% CI)P valueAIRR* (95% CI)P value
Any postrelease opioid† use (n=203)
1. Ambulance contacts 610.30 (0.80)
  OAT: none350.37 (0.79)1.001.00
  OAT: partial110.32 (0.88)0.88 (0.39 to 1.96)0.7510.57 (0.21 to 1.49)0.248
  OAT: retained150.20 (0.77)0.60 (0.30 to 1.19)0.1460.34 (0.14 to 0.83)0.018
2. ED contacts 1040.51 (1.19)
  OAT: none620.66 (1.25)1.001.00
  OAT: partial140.41 (1.08)0.67 (0.33 to 1.37)0.2730.45 (0.19 to 1.09)0.078
  OAT: retained280.37 (1.15)0.62 (0.36 to 1.08)0.0920.37 (0.18 to 0.76)0.006
15 or more days of opioid† use in the 30 days before follow-up (n=139)
1. Ambulance contacts 440.32 (0.84)
  OAT: none180.50 (0.85)1.001.00
  OAT: partial110.39 (0.96)0.79 (0.32 to 1.99)0.6210.81 (0.26 to 2.58)0.724
  OAT: retained150.20 (0.77)0.44 (0.20 to 0.98)0.0450.34 (0.12 to 0.98)0.045
2. ED contacts‡ 650.47 (1.13)
  OAT: none240.67 (1.07)1.001.00
  OAT: partial130.46 (1.17)0.73 (0.31 to 1.72)0.4680.56 (0.19 to 1.67)0.300
  OAT: retained280.37 (1.15)0.59 (0.29 to 1.17)0.1280.39 (0.16 to 0.92)0.032
25 or more days of opioid† use in the month before follow-up (n=129)
  1. Ambulance contacts 390.30 (0.84)
  OAT: none110.44 (1.00)1.001.00
  OAT: partial110.44 (1.00)1.00 (0.37 to 2.68)0.9951.34 (0.39 to 4.69)0.642
  OAT: retained150.20 (0.77)0.48 (0.20 to 1.16)0.1020.41 (0.13 to 1.30)0.129
2. ED contacts‡ 600.47 (1.17)
  OAT: none200.69 (1.17)1.001.00
  OAT: partial120.48 (1.23)0.73 (0.29 to 1.82)0.4990.59 (0.18 to 1.93)0.383
  OAT: retained280.37 (1.15)0.56 (0.27 to 1.17)0.1220.38 (0.15 to 0.95)0.039
  • *Adjusted for age at baseline, Aboriginal and/or Torres Strait Islander, historical psychiatric admission, self-reported fair or poor health, times moved accommodation, count of general practitioner consultations, psychiatric well-being (GHQ-12 score) and any IDU since baseline interview.

  • †Opioids include heroin as well as licit and illicit pharmaceutical opioids including methadone, buprenorphine, morphine and oxycodone.

  • ‡Aboriginal and/or Torres Strait Islander omitted from analysis as no Aboriginal and/or Torres Strait Islander participant attended ED and used opioids at least 15 days in the month before follow-up interview.

  • GHQ-12, 12-item General Health Questionnaire; IDU, injecting drug use.